Filed: 08/16/2006

Serial No.: 10/550,715

Page 2 of 8

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application:

- 1-17. (Canceled)
- 18. (Currently Amended) An isolated complex of the Formula I or Formula II:

I

$$[(AV)_m-L1]_{n-Pr}$$

$$AV$$
—[L2-(Pr)_o]_p II

wherein:

m is an integer from 1-5;

n is an integer from 1-100;

o is an integer from 1-5;

p is an integer from 1-100;

AV is an antiviral compound;

L1 and L2 are polyvalent linkers covalently linking AV to Pr, or where L1 and L2 are absent;

Pr is a protein; and

wherein the complex possesses antiviral activity inhibits HIV in vivo.

- 19. (Original) The complex of Claim 18, wherein the antiviral compound is a peptide.
- 20. (Original) The complex of Claim 19 wherein the peptide has a mass of less than about 100 kDA.
- 21. (Original) The complex of Claim 19, wherein the peptide has a mass of less than about 30 kDA.

Applicant: Abelardo Silva et al. Serial No.: 10/550,715
Filed: 08/16/2006 Page 3 of 8

22. (Original) The complex of Claim 19, wherein the peptide has a mass of less than about 10 kDA.

- 23. (Original) The complex of Claim 19 wherein the peptide is a peptidomimetic.
- 24. (Currently Amended) The complex of Claim 19 wherein the peptide consists of up to 51 amino acids comprising a sequence selected from the group consisting of:
 - Y1-X-X-Y2-X-X-X-Y3-X-X-Y4-X-X-Y5-X-X-Y6, SEQ ID NO: 843;
 - Y1-X-X-Y2-X-X-X-Y3-X-X-Y4-X-X-Y5-X-X-Y6-Y7, SEQ ID NO: 844;
 - Y1-X-X-Y2-X-X-X-Y3-X-X-Y4-X-X-Y5-X-X-Y6-Y7-X-X-X-Y8, SEQ ID NO: 844;
 - Y1-X-X-Y2-X-X-Y3-X-X-Y4-X-X-Y5-X-X-Y6-Y7-X-X-Y8-X-Y9, SEQ ID NO: 846;
 - Y1-X-X-Y2-X-X-Y3-X-X-Y4-X-X-Y5-X-X-Y6-Y7-X-X-Y8-X-Y9-Y10, SEQ ID NO: 847:
 - Y1-X-X-Y2-X-X-Y3-X-X-Y4-X-X-Y5-X-X-Y6-Y7-X-X-Y8-X-Y9-Y10-X-X-Y11, SEQ ID NO: 848;
 - Y1-X-X-Y2-X-X-Y3-X-X-Y4-X-X-Y5-X-X-Y6-Y7-X-X-Y8-X-Y9-Y10-X-X-Y11-Y12, SEQ ID NO: 849;
 - Y1-X-X-Y2-X-X-Y3-X-X-Y4-X-X-Y5-X-X-Y6-Y7-X-X-Y8-X-Y9-Y10-X-X-Y11-Y12-X-X-Y13, SEQ ID NO: 850;
 - Y1-X-X-Y2-X-X-Y3-X-X-Y4-X-X-Y5-X-X-Y6-Y7-X-X-Y8-X-Y9-Y10-X-X-Y11-Y12-X-X-Y13-Y14, SEQ ID NO: 851;
 - Y2-X-X-Y3-X-X-Y4-X-X-Y5-X-X-Y6-Y7-X-X-Y8-X-Y9-Y10-X-X-Y11-Y12-X-X-Y13-Y14, SEO ID NO: 852;
 - Y3-X-X-Y4-X-X-Y5-X-X-Y6-Y7-X-X-Y8-X-Y9-Y10-X-X-Y11-Y12-X-X-Y13-Y14, SEQ ID NO: 852;
 - Y4-X-X-Y5-X-X-Y6-Y7-X-X-Y8-X-Y9-Y10-X-X-Y11-Y12-X-X-Y13-Y14, SEQ ID NO: 854;
 - Y5-X-X-Y6-Y7-X-X-Y8-X-Y9-Y10-X-X-Y11-Y12-X-X-Y13-Y14, SEQ ID NO: 855; Y6-Y7-X-X-Y-Y9-Y10-X-X-Y11-Y12-X-X-Y13-Y14, SEQ ID NO: 856;

Serial No.: 10/550,715 Page 4 of 8

Applicant: Abelardo Silva et al. Filed: 08/16/2006

W-X-X-W-X-X-I-X-X-T-X-X-I-X-X-L-I-X-X-Q-X-Q-Q-X-X-N, SEQ ID NO: 857;

W-X1-X2-W-X3-X4-X5-I-X6-X7-X8-T-X9-X10-I-X11-X12-L-I-X13-X14-X15-Q-X16-Q-Q-X17-X18-N-X19-X20-X21-X22-X23, SEQ ID NO: [[857]] 858;

peptide DP178 (T-20); and

peptide T-1249;

wherein:

Y1 is selected from the group consisting of W, Y, F, H, L, N, Q, E, D, K, and R;

Y2 is selected from the group consisting of W, Y, F, H, L, N, O, E, D, K, and R:

Y3 is selected from the group consisting of I, V, L, A, S and T;

Y4 is selected from the group consisting of T, S, I, K, N, H, R, Q, E and D;

Y5 is selected from the group consisting of I, V, T, K, L, N, O, D, E, R and H;

Y6 is selected from the group consisting of any amino acid except P, G and C;

Y7 is selected from the group consisting of I, L, V, N, Q, K, R, H, E and D;

Y8 is selected from the group consisting of Q, H, R,N, E, D, K and P;

Y9 is selected from the group consisting of Q, H, N, E, D, K, R, L and P;

Y10 is selected from the group consisting of Q, H, N, E, D, K and R;

Y11 is selected from the group consisting of N, S, T, V, A and D;

Y12 is selected from the group consisting of E, V, K, G, R, Q, D, N, H, T and S;

Y13 is selected from the group consisting of L, I, V, K and R;

Y14 is selected from the group consisting of L, S, M, Y, N, Q, E, D, K, and R;

X1 is selected from the group consisting of M, L, I, Q, T, R and K;

X2 is either E, D, Q and K;

X3 is selected from the group consisting of E, D and K;

X4 is selected from the group consisting of K, R, E, Q, N and T;

X5 is selected from the group consisting of E, L, R, K and Q;

X6 is selected from the group consisting of N, D, S, E, Q, K, R, H, T, I and G;

X7 is selected from the group consisting of N, Q, D, E, K, S, T and Y;

X8 is selected from the group consisting of Y, F, H, I, V and S;

Serial No.: 10/550,715 Page 5 of 8

Applicant: Abelardo Silva et al. Filed: 08/16/2006

X9 is selected from the group consisting of G, K, R, H, D, E, S, T, N and Q;

X10 is selected from the group consisting of K, H, E, Q, T, V, I, L, M, A, Y, F, and P;

X11 is selected from the group consisting of H, K, E, Y and F;

X12 is selected from the group consisting of T, S, Q, N, E, D, R, K, H, W, G, A, and M;

X13 is selected from the group consisting of D, E, Q, T, K, R, A, V and G;

X14 is selected from the group consisting of D, E, K, H, Q, N, S, I, L, V, A and G;

X15 is selected from the group consisting of S, A and (P);

X16 is selected from the group consisting of N, K, S, T, D, E, Y, I and V;

X17 is selected from the group consisting of E, D, N, K, G, and V;

X18 is selected from the group consisting of K, R, H, D, E, N, Q, T, M, I, and Y;

X19 is selected from the group consisting of E, V, Q, M, L, J, and G;

X20 is selected from the group consisting of Q, N, E, K, R, H, L, and F;

X21 is selected from the group consisting of E, D, N, S, K, A, and G;

X22 is selected from the group consisting of L, I, and Y; and

X23 is selected from the group consisting of I, L, M, Q, S, and Y.

- 25. (Original) The complex of Claim 24 wherein the protein is a blood component.
- 26. (Original) The complex of Claim 25, wherein the blood component is selected from the group consisting of red blood cells, immunoglobulins, IgM, IhG, serum albumin, transferrin, P90 and P38, ferritin, a steroid binding protein, thyroxin binding protein, and α -2-macroglobulin.
- 27. (Original) The complex of Claim 25, wherein the blood component is human serum albumin and the linker is a peptide linker.
- 28. (Original) The complex of Claim 25, wherein the blood component is human serum albumin and the linker is a non-peptide linker.

Applicant: Abelardo Silva et al.

Filed: 08/16/2006

Serial No.: 10/550,715
Page 6 of 8

29. (Canceled)

- 30. (Original) The complex of Claim 18, wherein the linker L1 or L2 is a non-labile linker that is stable toward hydrolytic cleavage *in vivo*.
 - 31-145. (Canceled)